Brief: Ironwood Pharmaceuticals Reports Positive Topline Data From Phase Iii Trial Of Linzess® (Linaclotide) In Pediatric Patients Aged 6-17 With Functional Constipation
06/09/2022 12:53
Sept 6 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O :
* IRONWOOD PHARMACEUTICALS REPORTS POSITIVE TOPLINE DATA
FROM
PHASE III TRIAL OF LINZESS® (LINACLOTIDE) IN PEDIATRIC PATIENTS
AGED 6-17 WITH FUNCTIONAL CONSTIPATION
* IRONWOOD PHARMACEUTICALS INC - STUDY MET PRIMARY AND
SECONDARY
ENDPOINTS -- RESULTS ADD TO BODY OF DATA SUPPORTING SAFETY OF
LINACLOTIDE
* IRONWOOD PHARMACEUTICALS INC - IRONWOOD AND ITS PARTNER,
ABBVIE,
TO EVALUATE A POTENTIAL SUPPLEMENTAL NEW DRUG APPLICATION (SNDA)
SUBMISSION
Source text for Eikon: ID:nBwVXwTca
Further company coverage: IRWD.O
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation